Elutia (ELUT) EBT Margin (2019 - 2026)

Elutia (ELUT) posted EBT Margin of 251.25% for Q1 2026, down 26.03% sequentially from 199.36% in Q4 2025, and down 18758.0% YoY from N/an in Q1 2025.

Elutia (ELUT) EBT Margin (2019 - 2026) Analysis & Trends

Elutia has reported EBT Margin for 8 years, with the latest figure at 251.25% in Q1 2026.

Quarterly EBT Margin fell 18758.0% year-over-year to 251.25% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 152.29% (up 6435.0% YoY) and the FY2025 annual result came in at 129.0%, up 18439.0% from the prior year.
EBT Margin retreated to 251.25% in Q1 2026 per ELUT's latest filing, from 199.36% in the prior quarter.
Over five years, EBT Margin peaked at 91.4% in Q3 2024 and troughed at 450.98% in Q2 2024.
A 5-year average of 156.37% and a median of 152.83% in 2023 frame the typical range for EBT Margin.
The sharpest annual moves came in 2024 and 2025: EBT Margin tumbled 32945 bps in 2024, then jumped 29766 bps in 2025.
Over 5 years, EBT Margin stood at 91.35% in 2022, then tumbled by 184 bps to 259.23% in 2023, then rose by 2 bps to 254.01% in 2024, then climbed by 22 bps to 199.36% in 2025, then declined by 26 bps to 251.25% in 2026.
According to Business Quant data, EBT Margin over the past three periods registered 251.25%, 199.36%, and 11.28% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Abbott Laboratories	198.70 Bn	193.10 Bn	7.27 Bn	12.10%
2	Stryker	125.85 Bn	122.37 Bn	4.50 Bn	23.74%
3	Medtronic	118.44 Bn	109.22 Bn	6.41 Bn	18.70%
4	Boston Scientific	72.64 Bn	72.10 Bn	3.85 Bn	19.48%
5	Edwards Lifesciences	51.94 Bn	47.69 Bn	1.35 Bn	29.86%
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn	24.27%
7	GE HealthCare Technologies	33.60 Bn	31.49 Bn	2.18 Bn	13.09%
8	Koninklijke Philips	26.30 Bn	22.98 Bn	4.55 Bn	8.91%
9	Steris	23.00 Bn	22.52 Bn	684.20 Mn	18.32%
10	Elutia	39.87 Mn	19.98 Mn	1.45 Mn	-314.71%

Download Data